logo-loader
viewAvacta Group PLC

Avacta Group PLC agrees major co-development partnership with US business

Alastair Smith, chief executive of Avacta Group Plc (LON: AVCT), discusses with Proactive's Andrew Scott a co-development partnership that's been agreed with a US business.

Smith says they're teaming up with Bach BioSciences, a company commercialising the research of William Bachovchin, a professor at Tufts University School of Medicine, Boston.

In what is described as a “ground-breaking” co-invention, the two companies have developed a new class of drug conjugate for cancer.

Quick facts: Avacta Group PLC

Price: 139.5 GBX

AIM:AVCT
Market: AIM
Market Cap: £291.27 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Australian Potash cashed up as it works to round off FEED programme at Lake...

Australian Potash Ltd's (ASX:APC) Matt Shackleton speaks to Proactive's Andrew Scott after raising close to $2.23mln via a rights offer which complements the $2mln placement completed in April this year. Following the release of the Definitive Feasibility Study (DFS) in August 2019, APC is...

6 hours, 47 minutes ago

2 min read